01—Abstract
Summary
Summary of the 10-K filed June 22, 2023. Cited figures are marked; the original filing is the authoritative source.
Medtronic plc (MDT) filed its 10-K for the fiscal year ending April 27, 2023, reporting total net sales of $31.2 billiona.
While overall sales saw a slight decrease of 1%b compared to the prior year, this was largely attributed to unfavorable currency impacts, particularly in developed markets, and ongoing supply chain challenges. The company's strategic focus remains on leveraging its pipeline, accelerating innovation, and improving operational nimbleness across its four key segments: Cardiovascular, Medical Surgical, Neuroscience, and Diabetes. Despite the slight top-line dip, Medtronic highlighted growth in key areas such as Micra transcatheter pacing systems, transcatheter aortic valve replacements (TAVR), and neurovascular therapies.
The company also reported progress in its ESG initiatives and a strong commitment to employee development and an inclusive workplace. Management anticipates continued focus on innovation and market expansion, particularly in emerging markets, while navigating macroeconomic headwinds such as inflation, rising interest rates, and geopolitical factors.
02—Key points
Key Highlights
- Total net sales for fiscal year 2023 were $31.2 billion, a 1% decrease from fiscal year 2022, primarily due to unfavorable currency impacts and supply chain challenges.
- The Cardiovascular segment showed growth, with net sales increasing 1% to $11.6 billion, driven by strong performance in Micra pacing systems and TAVR, partially offset by currency headwinds.
- The Medical Surgical Portfolio experienced an 8% decline in net sales to $8.4 billion, impacted by reduced ventilator demand compared to the prior year and supply chain issues.
- The Neuroscience Portfolio saw a 2% increase in net sales to $9.0 billion, driven by growth in spine, neurovascular, and ENT products, with acquisitions contributing positively.
- The Diabetes Operating Unit's net sales decreased by 3% to $2.3 billion, primarily due to unfavorable currency impacts and domestic market challenges, though international growth for the MiniMed 780G system showed promise.
- Medtronic reported $4.6 billion in free cash flow for fiscal year 2023.
- The company continued its share repurchase program, with approximately $2.4 billion remaining under the authorized program as of April 28, 2023, and announced an increase in its quarterly cash dividend.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2023, Medtronic plc kept $0.12.
- Revenue$31.23B100.0%
- Cost of revenue−$10.72B34.3%
- Gross profit$20.51B65.7%
- Operating costs−$15.02B48.1%
- Operating income$5.49B17.6%
- Interest, other & tax−$1.70B5.4%
- Net income$3.78B12.1%
Where FY2023 revenue went
$31.23B- Cost of revenue: $10.72B, 34% of revenue
- SG&A: $10.41B, 33% of revenue
- Other operating costs: $4.61B, 15% of revenue
- Net income: $3.78B, 12% of revenue
- Interest, other & tax: $1.70B, 5.4% of revenue
Kept 12% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2023filed June 22, 2023Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $31.23B$31.69B | −1.4% |
| Cost of Revenue | $10.72B$10.14B | +5.7% |
| Gross Profit | $20.51B$21.54B | −4.8% |
| SG&A Expenses | $10.41B$10.29B | +1.2% |
| Operating Income | $5.49B$5.75B | −4.6% |
| Interest Expense | $636.00M$553.00M | +15.0% |
| Net Income | $3.78B$5.06B | −25.2% |
| EPS (Basic) | $2.83$3.75 | −24.5% |
| EPS (Diluted) | $2.82$3.73 | −24.4% |
| Shares Outstanding (Basic) | 1.33B1.34B | −0.9% |
| Shares Outstanding (Diluted) | 1.33B1.35B | −1.4% |
05—Questions
Frequently Asked Questions
What was Medtronic's overall financial performance in fiscal year 2023?
Medtronic reported total net sales of $31.2 billion for the fiscal year ended April 27, 2023, which represents a slight decrease of 1% compared to fiscal year 2022. This decrease was primarily attributed to unfavorable currency exchange rates and ongoing supply chain disruptions. Despite the slight sales decline, the company generated $4.6 billion in free cash flow and continued to return capital to shareholders through dividends and share repurchases.
Which segments performed strongest and weakest in fiscal year 2023?
The Cardiovascular segment performed strongest, with a 1% increase in net sales to $11.6 billion, driven by growth in its Micra pacing systems and TAVR products. The Neuroscience segment also showed growth, with a 2% increase in net sales to $9.0 billion, bolstered by acquisitions and strong performance in spine and neurovascular products. The Medical Surgical Portfolio experienced the weakest performance, with an 8% decrease in net sales to $8.4 billion, mainly due to reduced demand for ventilators and supply chain challenges.
What are Medtronic's key strategic priorities moving forward?
Medtronic's strategy revolves around four key areas: leveraging its pipeline to accelerate revenue growth, serving more patients by accelerating innovation and delivering shareholder value, creating and disrupting markets with its technology, and empowering its operating units to be more nimble and competitive. The company plans to achieve this by continuing to invest in R&D, focusing on disruptive technologies like AI, expanding into emerging markets, and driving operational efficiencies.
How did currency fluctuations impact Medtronic's financial results?
Currency fluctuations had a notable negative impact on Medtronic's net sales in fiscal year 2023, particularly in non-U.S. developed markets, where it unfavorably impacted sales by $569 million in the Cardiovascular segment alone, and $454 million in the Medical Surgical segment. Across all non-U.S. markets, the unfavorable currency impact on net sales was approximately $1.2 billion in developed markets and $262 million in emerging markets.
06—Continue